Literature DB >> 16508951

Restrained molecular dynamics simulations of HIV-1 protease: the first step in validating a new target for drug design.

Alexander L Perryman1, Jung-Hsin Lin, J Andrew McCammon.   

Abstract

To test the anticorrelated relationship that was recently displayed in conventional molecular dynamics (MD) simulations, several different restrained MD simulations on a wild type and on the V82F/I84V drug-resistant mutant of HIV-1 protease were performed. This anticorrelated relationship refers to the observation that compression of the peripheral ear-to-cheek region of HIV protease (i.e., the elbow of the flap to the fulcrum and the cantilever) occurred as the active site flaps were opening, and, conversely, expansion of that ear-to-cheek region occurred as both flaps were closing. An additional examination of this anticorrelated relationship was necessary to determine whether it can be harnessed in a useful manner. Consequently, six different MD experiments were performed that incorporated pairwise distance restraints in that ear-to-cheek region (i.e., the distance between the alpha-carbons of Gly40 and Gln61 was restrained to either 7.7 or 10.5 A, in both monomers). Pushing the backbones of the ear and the cheek regions away from each other slightly did force the flaps that guard the active site to remain closed in both the wild type and the mutant systems-even though there were no ligands in the active sites. Thus, these restrained MD simulations provided evidence that the anticorrelated relationship can be exploited to affect the dynamic behavior of the flaps that guard the active site of HIV-1 protease. These simulations supported our hypothesis of the mechanism governing flap motion, and they are the first step towards validating that peripheral surface as a new target for drug design.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16508951     DOI: 10.1002/bip.20497

Source DB:  PubMed          Journal:  Biopolymers        ISSN: 0006-3525            Impact factor:   2.505


  22 in total

1.  Structural and biochemical characterization of the inhibitor complexes of xenotropic murine leukemia virus-related virus protease.

Authors:  Mi Li; Alla Gustchina; Krisztina Matúz; Jozsef Tözsér; Sirilak Namwong; Nathan E Goldfarb; Ben M Dunn; Alexander Wlodawer
Journal:  FEBS J       Date:  2011-10-10       Impact factor: 5.542

Review 2.  Targeting structural flexibility in HIV-1 protease inhibitor binding.

Authors:  Viktor Hornak; Carlos Simmerling
Journal:  Drug Discov Today       Date:  2006-12-20       Impact factor: 7.851

3.  The open structure of a multi-drug-resistant HIV-1 protease is stabilized by crystal packing contacts.

Authors:  Melinda Layten; Viktor Hornak; Carlos Simmerling
Journal:  J Am Chem Soc       Date:  2006-10-18       Impact factor: 15.419

4.  Atomistic simulations of the HIV-1 protease folding inhibition.

Authors:  Gennady Verkhivker; Guido Tiana; Carlo Camilloni; Davide Provasi; Ricardo A Broglia
Journal:  Biophys J       Date:  2008-03-28       Impact factor: 4.033

5.  Insights into the dynamics of HIV-1 protease: a kinetic network model constructed from atomistic simulations.

Authors:  Nan-jie Deng; Weihua Zheng; Emillio Gallicchio; Ronald M Levy
Journal:  J Am Chem Soc       Date:  2011-05-25       Impact factor: 15.419

6.  Identifying binding hot spots on protein surfaces by mixed-solvent molecular dynamics: HIV-1 protease as a test case.

Authors:  Peter M U Ung; Phani Ghanakota; Sarah E Graham; Katrina W Lexa; Heather A Carlson
Journal:  Biopolymers       Date:  2016-01       Impact factor: 2.505

7.  Cooperative effects of drug-resistance mutations in the flap region of HIV-1 protease.

Authors:  Jennifer E Foulkes-Murzycki; Christina Rosi; Nese Kurt Yilmaz; Robert W Shafer; Celia A Schiffer
Journal:  ACS Chem Biol       Date:  2012-12-27       Impact factor: 5.100

8.  A poke in the eye: inhibiting HIV-1 protease through its flap-recognition pocket.

Authors:  Kelly L Damm; Peter M U Ung; Jerome J Quintero; Jason E Gestwicki; Heather A Carlson
Journal:  Biopolymers       Date:  2008-08       Impact factor: 2.505

9.  Co-lethality studied as an asset against viral drug escape: the HIV protease case.

Authors:  Sophie Brouillet; Thomas Valere; Emmanuelle Ollivier; Laurent Marsan; Anne Vanet
Journal:  Biol Direct       Date:  2010-06-17       Impact factor: 4.540

10.  Insights into drug resistance of mutations D30N and I50V to HIV-1 protease inhibitor TMC-114: free energy calculation and molecular dynamic simulation.

Authors:  Jianzhong Chen; Shaolong Zhang; Xinguo Liu; Qinggang Zhang
Journal:  J Mol Model       Date:  2009-07-24       Impact factor: 1.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.